Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,552.35 +1,687.64 (+2.73%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
China Pharma Holdings, Inc. (CPHI)
After hours:
| Previous close | 0.3034 |
| Open | 0.3119 |
| Bid | 0.2920 x 1200 |
| Ask | 0.3148 x 1000 |
| Day's range | 0.3003 - 0.3217 |
| 52-week range | 0.2700 - 2.2000 |
| Volume | |
| Avg. volume | 427,470 |
| Market cap | 4.716M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-302.
- PR Newswire
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.
